Quantitative Risk/Benefit Assessment: Where Are We?
Pharmaceutical sponsors use a variety of approaches to make important benefit/risk decisions about their products internally. Benefit/risk assessment is equally important when regulators evaluate a product for marketing approval and payers evaluate it for reimbursement decision. Once a product receives marketing authorization, it is critical to communicate pertinent benefit and risk information to patients and health-care providers. All of the above can be made easier by the use of a common framework. In this paper, we review where we are in benefit/risk assessment. This includes endeavors by academic institutions, regulators, and the pharmaceutical industry. Despite concerns about quantitative benefit/risk assessment expressed by some, we argue that without a way to quantitatively incorporate the relative importance of factors impacting benefit/risk assessment, it will be hard to bring transparent decisions to questions such as “does the benefit of this product outweigh the risk.”
KeywordsToxicity Europe Marketing Warfarin Hydrochloride
The author wants to thank Jon Norton for the use of Fig. 2. The author also wants to thank PhRMA BRAT, especially Bennett Levitan, Paul Coplan, Rebecca Noel, Marilyn Metcalf, and Diana Hughes, for BRAT-generated materials. In addition, the author wants to thank Leila Zelnick and Tom Fleming for their comments which have helped improve the quality of the paper.
- 10.Entsuah R, Gao B (2002) Global benefit-risk evaluation of antidepressant action: comparison of pooled data for venlafaxine, SSRIs and placebo. CNS Spectr 7:882–888Google Scholar
- 12.Norton J (2010) A longitudinal model for medical benefit-risk analysis, with case study. Presented at the 19th Annual International Chinese Statistical Association Applied Statistics Symposium, Indianapolis, IN, June 20–23Google Scholar
- 13.Norton J (2011) A longitudinal model and graphic for benefit-risk analysis, with case study. Drug Inf J 45:741–747Google Scholar
- 21.Hoerl RW, Snee RD (2010) Statistical engineering: an idea whose time has come? A discussion in honor of Gerry Hahn’s 80th birthday. Presented at the Joint Statistical Meetings, Vancouver British Columbia, August 1–5Google Scholar
- 23.Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM (2007) TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015CrossRefGoogle Scholar